Search Ontology:
ChEBI

lixisenatide

Term ID
CHEBI:85662
Synonyms
  • Adlyxin
  • AQVE-10010
  • AVE 0010
  • AVE0010
  • des-38-proline-exendine-4 (Heloderma suspectum)-(1-39)-peptidylpenta-L-lysyl-L-lysinamide
  • DesPro38Exendin-4(1-39)-Lys6-NH2
  • H-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2
  • H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH2
  • H-L-His-Gly-L-Glu-Gly-L-Thr-L-Phe-L-Thr-L-Ser-L-Asp-L-Leu-L-Ser-L-Lys-L-Gln-L-Met-L-Glu-L-Glu-L-Glu-L-Ala-L-Val-L-Arg-L-Leu-L-Phe-L-Ile-L-Glu-L-Trp-L-Leu-L-Lys-L-Asn-Gly-Gly-L-Pro-L-Ser-L-Ser-Gly-L-Ala-L-Pro-L-Pro-L-Ser-L-Lys-L-Lys-L-Lys-L-Lys-L-Lys-L-Lys
  • L-histidylglycyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-leucyl-L-seryl-L-lysyl-L-glutaminyl-L-methionyl-L-alpha-glutamyl-L-alpha-glutamyl-L-alpha-glutamyl-L-alanyl-L-valyl-L-arginyl-L-leucyl-L-phenylalanyl-L
  • lixisenatida
  • lixisenatide
  • lixisenatidum
  • Lyxumia
  • ZP 10
  • ZP10A peptide
Definition
A forty-four membered polypeptide consisting of L-His, Gly, L-Glu, Gly, L-Thr, L-Phe, L-Thr, L-Ser, L-Asp, L-Leu, L-Ser, L-Lys, L-Gln, L-Met, L-Glu, L-Glu, L-Glu, L-Ala, L-Val, L-Arg, L-Leu, L-Phe, L-Ile, L-Glu, L-Trp, L-Leu, L-Lys, L-Asn, Gly, Gly, LPro, L-Ser, L-Ser, Gly, L-Ala, L-Pro, L-Pro, L-Ser, L-Lys, L-Lys, L-Lys, L-Lys, L-Lys, and L-Lys-NH2 residues joined in sequence. Used as an adjunct to diet and exercise for the treatment of adults with type II diabetes.
References
  • cas:320367-13-3
  • drugcentral:4815
  • kegg.drug:D09729
  • pubmed:19629885
  • pubmed:21391833
  • pubmed:23537041
  • pubmed:23558600
  • pubmed:23825925
  • pubmed:23992745
  • pubmed:24086950
  • pubmed:24122776
  • pubmed:24363554
  • pubmed:24373190
  • pubmed:24476092
  • pubmed:24583037
  • pubmed:24641271
  • pubmed:24683832
  • pubmed:24876548
  • pubmed:25012990
  • pubmed:25027491
  • pubmed:25055456
  • pubmed:25066229
  • pubmed:25107586
  • pubmed:25115916
  • pubmed:25119443
  • pubmed:25130920
  • pubmed:25195184
  • pubmed:25773712
  • pubmed:25802728
  • pubmed:25853868
  • pubmed:25887358
  • pubmed:25965710
  • pubmed:26342556
  • pubmed:26423184
  • pubmed:26537183
  • pubmed:26594250
  • pubmed:26630143
  • pubmed:26701217
  • pubmed:26770666
  • pubmed:26787264
  • pubmed:26981945
  • pubmed:26981946
  • pubmed:26981947
  • pubmed:27092017
  • pubmed:27222510
  • pubmed:27252787
  • pubmed:27267268
  • pubmed:27284114
  • pubmed:27310712
  • pubmed:27311491
  • pubmed:27319011
  • pubmed:27341040
  • reaxys:23952540
  • wikipedia.en:Lixisenatide
Ontology
ChEBI  ( EBI )
Relationships
Phenotype
Phenotype resulting from lixisenatide
Phenotype where environments contain lixisenatide
Phenotype modified by environments containing lixisenatide
Phenotype affecting lixisenatide
Human Disease Model